Development and Verification of Time-Series Deep Learning for Drug-Induced Liver Injury Detection in Patients Taking Angiotensin II Receptor Blockers: A Multicenter Distributed Research Network Approach

• Published in: Healthcare informatics research Vol. 29; no. 3; pp. 246 - 255
• Main Authors: Heo, Suncheol, Yu, Jae Yong, Kang, Eun Ae, Shin, Hyunah, Ryu, Kyeongmin, Kim, Chungsoo, Chegal, Yebin, Jung, Hyojung, Lee, Suehyun, Park, Rae Woong, Kim, Kwangsoo, Hwangbo, Yul, Lee, Jae-Hyun, Park, Yu Rang
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society of Medical Informatics 01.07.2023; The Korean Society of Medical Informatics
• Subjects: adverse drug reaction; common data model; distributed research network; multicenter study; Original; time-series classification; Multicenter Study; Adverse Drug Reaction; Common Data Model; Time-Series Classification; Distributed Research Network
• DOI: 10.4258/hir.2023.29.3.246
• ISSN: 2093-3681; 2093-369X

The objective of this study was to develop and validate a multicenter-based, multi-model, time-series deep learning model for predicting drug-induced liver injury (DILI) in patients taking angiotensin receptor blockers (ARBs). The study leveraged a national-level multicenter approach, utilizing electronic health records (EHRs) from six hospitals in Korea. A retrospective cohort analysis was conducted using EHRs from six hospitals in Korea, comprising a total of 10,852 patients whose data were converted to the Common Data Model. The study assessed the incidence rate of DILI among patients taking ARBs and compared it to a control group. Temporal patterns of important variables were analyzed using an interpretable timeseries model. The overall incidence rate of DILI among patients taking ARBs was found to be 1.09%. The incidence rates varied for each specific ARB drug and institution, with valsartan having the highest rate (1.24%) and olmesartan having the lowest rate (0.83%). The DILI prediction models showed varying performance, measured by the average area under the receiver operating characteristic curve, with telmisartan (0.93), losartan (0.92), and irbesartan (0.90) exhibiting higher classification performance. The aggregated attention scores from the models highlighted the importance of variables such as hematocrit, albumin, prothrombin time, and lymphocytes in predicting DILI. Implementing a multicenter-based timeseries classification model provided evidence that could be valuable to clinicians regarding temporal patterns associated with DILI in ARB users. This information supports informed decisions regarding appropriate drug use and treatment strategies.